Literature DB >> 2460446

The expression of high molecular weight kininogen on human umbilical vein endothelial cells.

A H Schmaier1, A Kuo, D Lundberg, S Murray, D B Cines.   

Abstract

High molecular weight kininogen (HMWK) functions as a cofactor for activation of plasma serine zymogens and as an inhibitor of tissue cysteine proteases. Cell surfaces to which HMWK binds may provide sites for regulation of these systems. Localization of these HMWK-dependent processes at sites of vascular injury may depend on its binding to specific receptors on endothelial cells. In culture, passaged human umbilical vein endothelial cells (HUVEC) bind anti-HMWK antibody to the cell surface and contain 171 +/- 75 ng of HMWK/10(8) cells. [35S]Methionine-labeled HUVEC in culture synthesize a 120-kDa protein immunoisolated using an anti-kininogen antibody, and a 3500-nucleotide message for human HMWK was detected by Northern blot in RNA extracted from HUVEC. HUVEC also express unoccupied binding sites for HMWK on their surface. 125I-HMWK specifically binds to HUVEC in a reaction requiring Zn2+. 125I-HMWK binding to HUVEC is saturable at 4 degrees C but not at 23 degrees C. 125I-HMWK binds to HUVEC with equal affinity as unlabeled HMWK. Kallikrein, factor XII, fibrinogen, fibronectin, and thrombin do not inhibit 125I-HMWK binding to HUVEC. 125I-HMWK-HUVEC binding remains fully reversible at 60 min following the addition of a 50-fold molar excess HMWK. HUVEC express 9.3 +/- 2.0 X 10(5) (mean +/- S.E.) HMWK binding sites/cell (Kd = 52 +/- 13 nM). Both added and cell-bound 125I-HMWK migrate at 120 kDa on sodium dodecyl sulfate gel electrophoresis, suggesting that the protein remains uncleaved upon binding to the HUVEC surface. These studies indicate that HUVEC synthesize HMWK and the HUVEC surface has a site for its expression. By synthesizing and localizing HMWK to the cell surface, endothelial cells may contribute to the activation of plasma's contact serine zymogens and regulation of tissue cysteine proteases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460446

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level.

Authors:  M J Dumoulin; D Lamontagne; G Molinaro; A Adam
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

2.  Endothelial AT(2)-receptors: chicken or egg?

Authors:  Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

3.  Kinetics of inhibition of platelet calpain II by human kininogens.

Authors:  H N Bradford; A H Schmaier; R W Colman
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

Review 4.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

5.  Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R).

Authors:  K Joseph; B Ghebrehiwet; E I Peerschke; K B Reid; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

6.  Physiologic activities of the contact activation system.

Authors:  Alvin H Schmaier
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 7.  HAE Pathophysiology and Underlying Mechanisms.

Authors:  Bruce L Zuraw; Sandra C Christiansen
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

8.  Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

Authors:  R W Colman; R A Pixley; S Najamunnisa; W Yan; J Wang; A Mazar; K R McCrae
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

9.  Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.

Authors:  Sigurdur T Sigurdsson; Olaf B Paulson; Arne Høj Nielsen; Svend Strandgaard
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-11       Impact factor: 6.200

10.  B2 kinin receptor activation is the predominant mechanism by which trypsin mediates endothelium-dependent relaxation in bovine coronary arteries.

Authors:  Grant R Drummond; Stavros Selemidis; Thomas M Cocks
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.